Trevena Inc (TRVN) Given Average Recommendation of “Buy” by Brokerages

Trevena Inc (NASDAQ:TRVN) has been assigned a consensus recommendation of “Buy” from the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $8.65.

Several equities research analysts have recently commented on TRVN shares. Oppenheimer restated a “buy” rating and issued a $5.00 price objective on shares of Trevena in a research note on Monday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Trevena in a report on Wednesday, November 8th. Needham & Company LLC dropped their target price on shares of Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Wednesday, October 18th. Finally, Barclays downgraded shares of Trevena from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $15.00 to $2.50 in a report on Monday, October 16th.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its position in shares of Trevena by 37.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 980,440 shares of the biopharmaceutical company’s stock valued at $2,500,000 after buying an additional 268,825 shares in the last quarter. Bourgeon Capital Management LLC raised its position in shares of Trevena by 63.1% during the 3rd quarter. Bourgeon Capital Management LLC now owns 86,500 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 33,469 shares in the last quarter. Northpointe Capital LLC raised its position in shares of Trevena by 5.0% during the 3rd quarter. Northpointe Capital LLC now owns 1,283,025 shares of the biopharmaceutical company’s stock valued at $3,272,000 after buying an additional 61,546 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Trevena by 0.5% during the 2nd quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 500 shares in the last quarter. Finally, State Street Corp raised its position in Trevena by 8.3% in the 2nd quarter. State Street Corp now owns 768,249 shares of the biopharmaceutical company’s stock worth $1,767,000 after purchasing an additional 58,895 shares during the period. Hedge funds and other institutional investors own 56.10% of the company’s stock.

Shares of Trevena (TRVN) opened at $1.61 on Monday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.92 and a current ratio of 4.92. The firm has a market cap of $99.06, a price-to-earnings ratio of -0.98 and a beta of -0.58. Trevena has a 12 month low of $1.35 and a 12 month high of $8.00.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.06. During the same period in the previous year, the business earned ($0.57) earnings per share. equities research analysts predict that Trevena will post -1.23 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Trevena Inc (TRVN) Given Average Recommendation of “Buy” by Brokerages” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.com-unik.info/2017/12/25/trevena-inc-trvn-given-average-recommendation-of-buy-by-brokerages.html.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

What are top analysts saying about Trevena? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trevena and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit